European Primary Care Cardiovascular Society

CODE-EHR, a framework for the use of electronic health record data in clinical research

5' education - Oct. 13, 2022 - Prof. Folkert Asselbergs, MD, PhD

Risk of CVD in patients with autoimmune diseases

5' education - Oct. 12, 2022 - Prof. Naveed Sattar, MD, PhD

DOAC versus VKA in rheumatic atrial fibrillation

3' education - Sep. 15, 2022 - Prof. Ganesan Karthikeyan, MD

What are the real effects of statins on muscle symptoms?

3' education - Sep. 12, 2022 - Prof. Colin Baigent, MD

Aspirin or P2Y12i monotherapy for secondary prevention in patients with CAD?

3' education - Sep. 5, 2022 - Prof. Marco Valgimigli, MD, PhD

Long-term use of PCSK9i reduces CV events in ASCVD

3' education - Aug. 29, 2022 - Michelle O'Donoghue, MD

Smartphone-based screening more than doubles detection rate of atrial fibrillation

3' education - Aug. 28, 2022 - Prof. Axel Bauer, MD

A community-based screening trial for CVD

3' education - Aug. 28, 2022 - Prof. Axel Diederichsen, MD

Improved outcomes with SGLT2i in HFpEF and HFmrEF

3' education - Aug. 27, 2022 - Prof. Scott Solomon, MD

Patients with heart failure benefit from SGLT2i regardless of ejection fraction

3' education - Aug. 27, 2022 - Prof. Pardeep Jhund, MD, PhD

ARNI has no negative effect on cognitive function

3' education - Aug. 26, 2022 - Prof. John McMurray, MD

A discussion on CV risk reduction beyond statin therapy: Exploring the role of Icosapent ethyl

10' education - June 20, 2022 - Prof. Ulrich Laufs, MD, PhD, prof. Chris Packard, PhD and prof. Wouter Jukema, MD, PhD

What are potential mechanisms of benefit of icosapent ethyl?

10' education - June 20, 2022 - Prof. Chris Packard, PhD

Need to restart and catch up in CVD prevention in time of COVID-19

10' education - June 2, 2022 - Prof. Richard Hobbs, MD

Key findings of CV outcomes trials with icosapent ethyl

10' education - May 18, 2022 - Prof. Wouter Jukema, MD, PhD

Triglyceride-rich lipoproteins as residual CV risk in patients on statins

10' education - May 8, 2022 - Prof. Alberto Zambon, MD, PhD

Dietary education in the grocery store: a novel form of CV research

3' education - Apr. 19, 2022 - Prof. Eileen Handberg, PhD

Treating elevated Lp(a): beginning of an era

3' education - Apr. 16, 2022 - Steven Nissen, MD

Potassium binder results in optimization of RAASi and low risk of hyperkalemia in HFrEF

3' education - Apr. 14, 2022 - Prof. Javed Butler, MD

Quality of care improved with EHR-based intervention for patients with HF

3' education - Apr. 13, 2022 - Tariq Ahmad, MD

Association between cumulative systolic blood pressure load and cardiovascular events in diabetes

Literature - Jan. 5, 2023 - Wang N et al. - J Am Coll Cardiol. 2022

In a post-hoc analysis of the ADVANCE trial, cumulative SBP load was a better predictor of the occurrence of MACE in patients with T2DM compared with other BP measures.

Lp(a) levels in children with popable FH and definite FH

Literature - Dec. 6, 2022 - De Boer LM, et al. - Eur Heart J. 2022

A Dutch cross-sectional study showed that Lp(a) levels were higher and more often elevated in children with a clinical presentation of FH in whom no FH-causing mutation was detected compared with children with a mutation and their unaffected siblings.

Low adherence and persistence with HF therapies in newly diagnosed HF patients

Literature - Nov. 29, 2022 - Ødegaard KM, et al. - ESC Heart Fail. 2022

A Norwegian nationwide cohort study showed that in newly diagnosed HF patients, 1-year adherence to dual or triple HF therapies was low and 2- to 5-year persistence was inadequate.

Physical activity in the morning associated with reduced CVD risk

Literature - Nov. 28, 2022 - Albalak G, et al. - Eur J Prev Cardiol. 2022

Sufficient physical activity lowers the risk of CV mortality and improves quality of life. However, little is known about the association between timing of physical activity and CVD risk in the general population.

Efficacy and safety of PCSK9 siRNA in primary prevention

Literature - Nov. 23, 2022 - Ray KK, et al. - Eur Heart J. 2022

In an ORION-11 substudy, inclisiran reduced LDL-c, non-HDL-c and apoB levels in a subgroup of high-risk patients with elevated LDL-c but without prior CV events receiving maximally tolerated statin therapy.

Antihypertensive treatment associated with lower risk of dementia

Literature - Nov. 21, 2022 - Peters R et al. - Eur Heart J. 2022

In a meta-analysis of pooled individual participant data from 5 double-blind placebo-controlled RCTs, antihypertensive treatment was associated with a lower dementia risk compared with placebo.

Reduced worsening of kidney disease or CV death by SGLT2 inhibitor in CKD

News - Nov. 7, 2022

AHA 2022 In the EMPA-KIDNEY trial, use of empagliflozin reduced the outcome of worsening of kidney disease or CV death compared with placebo in CKD patients. In addition, results of a meta-analysis of 13 SGLT2i trials in high-risk patients were presented.

Mindfulness could lower elevated blood pressure

News - Nov. 7, 2022

AHA 2022 By participating in a mindfulness-based program, individuals with elevated office blood pressure (BP) could lower their systolic BP by 4.5 mmHg within 6 months compared with enhanced usual care.

Effect of dietary supplements on cholesterol compared with low-dose statin and placebo

News - Nov. 7, 2022

AHA 2022 In individuals with an increased 10-year ASCVD risk, rosuvastatin 5 mg daily reduced LDL-c, TC, and TG more than fish oil, cinnamon, garlic, turmeric, plant sterols, red yeast rice, or placebo. Moreover, no supplements reduced LDL-c significantly compared with placebo.

CRISPR/Cas9-based gene editing in patients with transthyretin amyloid cardiomyopathy

News - Nov. 6, 2022

AHA 2022 A phase I study investigated the safety, pharmacokinetics, and pharmacodynamics of NTLA-2001, a CRISPR/Cas9-based in vivo gene editing therapy, in patients with transthyretin amyloidosis with cardiomyopathy.

Does low-frequency intermittent fasting reduce LDL-c?

Literature - Oct. 31, 2022 - Bartholomew CL et al. - Eur Heart J Open. 2021

In an RCT with 71 participants, low-frequency intermittent fasting for 26 weeks did not alter LDL-c levels compared with an ad libitum diet. However, it did lower insulin resistance and the metabolic syndrome score.

CODE-EHR, a framework for the use of electronic health record data in clinical research

5' education - Oct. 13, 2022 - Prof. Folkert Asselbergs, MD, PhD
What is CODE-EHR and why has this framework been developed? Prof. Asselbergs gives a brief overview in response to questions of Joris Holtrop.

CSI Barcelona What is CODE-EHR and why has this framework been developed? Prof. Asselbergs gives a brief overview in response to questions of Joris Holtrop.